Effect of deferiprone on nitric oxide production in thalassemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20140807001

Enrollment

Registered

2014-08-07

Start date

2014-08-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoglobin E/beta&#45

Interventions

Single oral dose of deferiprone (75 mg/kg),Single oral dose of deferiprone (75 mg/kg)

Experimental Drug,Experimental Drug

Healthy control subjects,Hemoglobin E/ beta&#45

thalassemia patients

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Hemoglobin E beta thalassemia Transfusion dependent thalassemia patients No iron chelator therapy for at least 1 month before study Clinically stable state

Exclusion criteria

Exclusion criteria: Hypersensitivity to deferiprone Pregnancy HIV positive Neutropenia Thrombocytopenia Drug or alcohol addiction

Design outcomes

Primary

Measure	Time frame
nitric oxide levels in blood 0, 0.5,1,2,3,4,6 h chemiluminescence method	—

Secondary

Measure	Time frame
Nontransferrin bound iron 0, 0.5,1,2,3,4,6 h Spectrophotometry,Blood pressure 0, 0.5,1,2,3,4,6 h Sphygmomanometer	—

Countries

Thailand

Contacts

Public ContactThanaporn Sriwantana

Pharmacology Department, Faculty of Science, Mahidol University

tsriwantana@hotmail.com6622015490

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026